[Artificial liver support systems: update on albumin dialysis (MARS)].

Autor: Catalina-Rodríguez MV; Sección de Hepatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. balcoval@teleline.es, Bañares-Cañizares R
Jazyk: Spanish; Castilian
Zdroj: Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2005 Oct; Vol. 28 (8), pp. 453-60.
DOI: 10.1157/13078996
Abstrakt: Mortality among patients with liver insufficiency continues to be unacceptably high. The prognosis of patients with acute episodes of chronic liver insufficiency is almost as poor as that of patients with acute liver failure. Therefore, systems that support liver function, either until liver transplantation can be performed or until resolution of the situation before acute injury occurs, are essential. Albumin dialysis is a system of artificial liver support that allows detoxification of albumin-related and hydrosoluble substances, thus maintaining the patient's homeostasis. Current clinical experience of this therapy is still limited, although beneficial effects on clinical, laboratory and hemodynamic parameters have been demonstrated. Multicenter, controlled trials to evaluate the effect of this therapy on survival in distinct diseases are needed.
Databáze: MEDLINE